Rebalancing gut microbiome lengthens survival in mouse model of ALS
A bacterial by-product known to be important in maintaining gut health may slow the progression of amyotrophic lateral sclerosis, or ALS – a progressive, neurodegenerative disease.
Researchers at the University of Illinois at Chicago College of Medicine report that in a mouse model of ALS, the compound butyrate helped correct a gut microbiome imbalance and reduced gut leakiness – both symptoms of ALS. The treated mice lived also longer compared to mice that weren’t given butyrate.
The finding is reported in Clinical Therapeutics.
ALS, also known as Lou Gehrig’s disease, slowly destroys the motor neurons that control movement. Patients gradually lose the ability to walk, speak and swallow — and eventually, to breathe. Conventional treatments include physical therapy and medications, but researchers have recently started looking to the gut as a new target for intervention.
“The brain and the gut are linked, so it’s not too surprising that the health of the gut can impact the functioning of neurons,” says Jun Sun, associate professor of gastroenterology and hepatology at UIC and corresponding author of the paper. In March, she and her coworkers were the first to identify a gut component to ALS progression.
The gut microbiome – the myriad bacteria, viruses and other microbes that make the gut their home – when in balance, helps maintain health, starting with the gut lining. Leaky gut in ALS may lead to increased inflammation. Reducing this gut-associated inflammation has been a goal of clinicians and researchers, and rebalancing the gut microbiome has shown promise in small-animal studies.
Sun and her colleagues studied transgenic mice that were engineered to carry human genes known to contribute to certain forms of ALS. The mice were found to have an abnormal microbiome, along with damaged junctions between the cells of the intestinal lining. Poorly functioning junctions can cause the tissue to become leaky, and have been found to be associated with the onset of ALS in humans.
When the researchers fed the ALS-prone mice butyrate in their water, starting when the mice were 35 to 42 days old, the mice showed a restored gut microbiome profile and improved gut integrity. Butyrate-treated mice also showed improved neuromuscular function and delayed onset of ALS symptoms. Treated mice showed symptoms at 150 days old compared to control mice at about 110 days. Treated mice also lived an average 38 days longer than mice not given butyrate.
“There is only one approved drug to treat ALS, so we need additional treatments,” Sun said. “Butyrate is a bacterial by-product, and already available over the counter as a supplement. Studies are needed to see its effects on ALS in humans, but our preliminary results in mice are very promising.”
Yongguo Zhang, Shaoping Wu, Yinglin Xia and Dapeng Jin of UIC and Jingsong Zhou and Jianxun Yi of the Kansas City University of Medicine and Bioscience are co-authors on the paper.
This research was funded in part by National Institutes of Health grants R01 DK105118, NIAMS R01 AR057404 and an ALS Association Research Award.